Scholar Rock Holding Corp. (SRRK)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$54.62-4.88%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
Scholar Rock aims to launch apitegromab by September 2026. The company plans to extend cash into 2027. It resubmitted its drug application to the FDA. These steps could lead to future growth.
FDA has rejected Scholar Rock's drug application multiple times. The company is losing money and missed earnings recently. Cash may run out before drug approval.
The price is about 9% below our fair value of $62. The market expects negative earnings growth over the next 3-5 years. Our view is cautious given regulatory risks.
Breaks if: Launch delayed beyond September 2026
Achieve FDA approval and commercial launch of apitegromab for SMA by the September 30, 2026 PDUFA date.
Stated as a priority in 2 of last 2 quarters. Management confirmed the FDA review of apitegromab's BLA is progressing with two fill-finish facilities and the U.S. commercial team is ready to launch immediately upon approval by the September 30, 2026 PDUFA date. No revenue was recorded in these quarters, consistent with pre-launch status. The trajectory matches management's stated goal of launching by the PDUFA date.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making but is working towards launching a new product, which could drive future growth.
The market appears to have priced in some expectations of future success, but there is a notable expectations gap. The valuation shows a premium compared to peers, indicating that investors are anticipating potential upside from the upcoming product launch.
Management is on track with its priorities, particularly in extending the cash runway into 2027. However, the recent financial performance has been mixed, with a history of earnings misses that could pose risks in the near term.
The long-term thesis hinges on the successful launch of apitegromab and the overall performance of the healthcare sector. Additionally, any changes in guidance or macroeconomic conditions could significantly impact the company's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The regulatory review and resubmission of the apitegromab BLA has advanced. This progress supports the timeline for the drug's approval. There are no new threats impacting the thesis at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Apitegromab BLA review by FDA continues to advance with two fill-finish facilities, representing two independent paths to FDA approval by September 30, 2026 PDUFA date.”
“FDA accepted apitegromab BLA with September 30, 2026 PDUFA action date; U.S. commercial team prepared to launch immediately upon FDA approval.”
Breaks if: Cash runs out before end of 2027
Breaks if: BLA not accepted by FDA within 6 months of resubmission
Resubmit the Biologics License Application (BLA) for apitegromab to the FDA.
Over the next 1 to 3 years, SRRK's success will depend on its ability to execute on its product launch and navigate sector dynamics. Not investment advice.